Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:cerdam01

Total Results:

296


Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals

Bushnell, Greta A; Rynn, Moira A; Gerhard, Tobias; Keyes, Katherine M; Hasin, Deborah S; Cerdá, Magdalena; Nyandege, Abner; Olfson, Mark
BACKGROUND AND AIMS/OBJECTIVE:Benzodiazepines (BZDs) carry a risk for drug overdose and are prescribed alone or simultaneously with selective-serotonin reuptake inhibitors (SSRIs) for the treatment of anxiety and depression in young adults. We aimed to measure risks of drug overdose following BZD treatment initiation, and simultaneous BZD and SSRI initiation, compared with SSRI treatment alone in young adults with depression or anxiety. DESIGN, SETTING, PARTICIPANTS/METHODS:The cohort study used administrative databases covering privately (MarketScan, 1/1/2009-12/31/2018) and publicly (Medicaid, 1/1/2015-12/31/2016) insured young adults (18-29 years) in the United States. Those with depression or anxiety diagnoses newly initiating BZD or SSRI treatment (without BZD or SSRI prescriptions in prior year) were included. Simultaneous "BZD + SSRI" initiation was defined as starting BZD and SSRI treatment on the same day. The cohorts included 604 664 privately insured young adults (BZD = 22%, BZD + SSRI = 10%, SSRI = 68%) and 110 493 publicly insured young adults (BZD = 23%, BZD + SSRI = 5%, SSRI = 72%). MEASUREMENTS/METHODS:Incident medically treated drug overdose events were identified from emergency department and inpatient encounters (ICD poisoning codes) within 6 months of treatment initiation. Crude and propensity-score adjusted cumulative incidence and hazard ratios (HR) were estimated. Sub-analyses evaluated drug overdose intent. FINDINGS/RESULTS:Adjusted HRs of drug overdose for BZD vs. SSRI treatment was 1.36 (95% confidence interval [CI]:1.23-1.51) in privately and 1.59 (95%CI:1.37-1.83) in publicly insured young adults. The adjusted HRs of drug overdose for BZD + SSRI treatment vs. SSRI treatment were 1.99 (95%CI:1.77-2.25) in privately and 1.98 (95%CI:1.47-2.68) in publicly insured young adults. CONCLUSIONS:Among young adults in the United States, initiating benzodiazepine treatment for anxiety and depression, alone or simultaneously with selective-serotonin reuptake inhibitors (SSRI), appears to have an increased risk of medically treated drug overdose compared with SSRI treatment alone. These associations were observed in publicly and privately insured individuals.
PMID: 37816665
ISSN: 1360-0443
CID: 5605012

Correction to: Scaling Interventions to Manage Chronic Disease: Innovative Methods at the Intersection of Health Policy Research and Implementation Science

McGinty, Emma E; Seewald, Nicholas J; Bandara, Sachini; Cerdá, Magdalena; Daumit, Gail L; Eisenberg, Matthew D; Griffin, Beth Ann; Igusa, Tak; Jackson, John W; Kennedy-Hendricks, Alene; Marsteller, Jill; Miech, Edward J; Purtle, Jonathan; Schmid, Ian; Schuler, Megan S; Yuan, Christina T; Stuart, Elizabeth A
PMID: 37395869
ISSN: 1573-6695
CID: 5524552

Scaling Interventions to Manage Chronic Disease: Innovative Methods at the Intersection of Health Policy Research and Implementation Science

McGinty, Emma E; Seewald, Nicholas J; Bandara, Sachini; Cerdá, Magdalena; Daumit, Gail L; Eisenberg, Matthew D; Griffin, Beth Ann; Igusa, Tak; Jackson, John W; Kennedy-Hendricks, Alene; Marsteller, Jill; Miech, Edward J; Purtle, Jonathan; Schmid, Ian; Schuler, Megan S; Yuan, Christina T; Stuart, Elizabeth A
Policy implementation is a key component of scaling effective chronic disease prevention and management interventions. Policy can support scale-up by mandating or incentivizing intervention adoption, but enacting a policy is only the first step. Fully implementing a policy designed to facilitate implementation of health interventions often requires a range of accompanying implementation structures, like health IT systems, and implementation strategies, like training. Decision makers need to know what policies can support intervention adoption and how to implement those policies, but to date research on policy implementation is limited and innovative methodological approaches are needed. In December 2021, the Johns Hopkins ALACRITY Center for Health and Longevity in Mental Illness and the Johns Hopkins Center for Mental Health and Addiction Policy convened a forum of research experts to discuss approaches for studying policy implementation. In this report, we summarize the ideas that came out of the forum. First, we describe a motivating example focused on an Affordable Care Act Medicaid health home waiver policy used by some US states to support scale-up of an evidence-based integrated care model shown in clinical trials to improve cardiovascular care for people with serious mental illness. Second, we define key policy implementation components including structures, strategies, and outcomes. Third, we provide an overview of descriptive, predictive and associational, and causal approaches that can be used to study policy implementation. We conclude with discussion of priorities for methodological innovations in policy implementation research, with three key areas identified by forum experts: effect modification methods for making causal inferences about how policies' effects on outcomes vary based on implementation structures/strategies; causal mediation approaches for studying policy implementation mechanisms; and characterizing uncertainty in systems science models. We conclude with discussion of overarching methods considerations for studying policy implementation, including measurement of policy implementation, strategies for studying the role of context in policy implementation, and the importance of considering when establishing causality is the goal of policy implementation research.
PMID: 36048400
ISSN: 1573-6695
CID: 5337802

Limits to Gauge Coupling in the Dark Sector Set by the Nonobservation of Instanton-Induced Decay of Super-Heavy Dark Matter in the Pierre Auger Observatory Data

Abreu, P; Aglietta, M; Albury, J M; Allekotte, I; Almeida Cheminant, K; Almela, A; Aloisio, R; Alvarez-Muñiz, J; Alves Batista, R; Ammerman Yebra, J; Anastasi, G A; Anchordoqui, L; Andrada, B; Andringa, S; Aramo, C; Araújo Ferreira, P R; Arnone, E; Arteaga Velázquez, J C; Asorey, H; Assis, P; Avila, G; Avocone, E; Badescu, A M; Bakalova, A; Balaceanu, A; Barbato, F; Bellido, J A; Berat, C; Bertaina, M E; Bhatta, G; Biermann, P L; Binet, V; Bismark, K; Bister, T; Biteau, J; Blazek, J; Bleve, C; Blümer, J; Boháčová, M; Boncioli, D; Bonifazi, C; Bonneau Arbeletche, L; Borodai, N; Botti, A M; Brack, J; Bretz, T; Brichetto Orchera, P G; Briechle, F L; Buchholz, P; Bueno, A; Buitink, S; Buscemi, M; Büsken, M; Caballero-Mora, K S; Caccianiga, L; Canfora, F; Caracas, I; Caruso, R; Castellina, A; Catalani, F; Cataldi, G; Cazon, L; Cerda, M; Chinellato, J A; Chudoba, J; Chytka, L; Clay, R W; Cobos Cerutti, A C; Colalillo, R; Coleman, A; Coluccia, M R; Conceição, R; Condorelli, A; Consolati, G; Contreras, F; Convenga, F; Correia Dos Santos, D; Covault, C E; Dasso, S; Daumiller, K; Dawson, B R; Day, J A; de Almeida, R M; de Jesús, J; de Jong, S J; de Mello Neto, J R T; De Mitri, I; de Oliveira, J; de Oliveira Franco, D; de Palma, F; de Souza, V; De Vito, E; Del Popolo, A; Del Río, M; Deligny, O; Deval, L; di Matteo, A; Dobre, M; Dobrigkeit, C; D'Olivo, J C; Domingues Mendes, L M; Dos Anjos, R C; Dova, M T; Ebr, J; Engel, R; Epicoco, I; Erdmann, M; Escobar, C O; Etchegoyen, A; Falcke, H; Farmer, J; Farrar, G; Fauth, A C; Fazzini, N; Feldbusch, F; Fenu, F; Fick, B; Figueira, J M; Filipčič, A; Fitoussi, T; Fodran, T; Fujii, T; Fuster, A; Galea, C; Galelli, C; García, B; Garcia Vegas, A L; Gemmeke, H; Gesualdi, F; Gherghel-Lascu, A; Ghia, P L; Giaccari, U; Giammarchi, M; Glombitza, J; Gobbi, F; Gollan, F; Golup, G; Gómez Berisso, M; Gómez Vitale, P F; Gongora, J P; González, J M; González, N; Goos, I; Góra, D; Gorgi, A; Gottowik, M; Grubb, T D; Guarino, F; Guedes, G P; Guido, E; Hahn, S; Hamal, P; Hampel, M R; Hansen, P; Harari, D; Harvey, V M; Haungs, A; Hebbeker, T; Heck, D; Hill, G C; Hojvat, C; Hörandel, J R; Horvath, P; Hrabovský, M; Huege, T; Insolia, A; Isar, P G; Janecek, P; Johnsen, J A; Jurysek, J; Kääpä, A; Kampert, K H; Keilhauer, B; Khakurdikar, A; Kizakke Covilakam, V V; Klages, H O; Kleifges, M; Kleinfeller, J; Knapp, F; Kunka, N; Lago, B L; Langner, N; Leigui de Oliveira, M A; Lenok, V; Letessier-Selvon, A; Lhenry-Yvon, I; Lo Presti, D; Lopes, L; López, R; Lu, L; Luce, Q; Lundquist, J P; Machado Payeras, A; Mancarella, G; Mandat, D; Manning, B C; Manshanden, J; Mantsch, P; Marafico, S; Mariani, F M; Mariazzi, A G; Mariş, I C; Marsella, G; Martello, D; Martinelli, S; Martínez Bravo, O; Mastrodicasa, M; Mathes, H J; Matthews, J; Matthiae, G; Mayotte, E; Mayotte, S; Mazur, P O; Medina-Tanco, G; Melo, D; Menshikov, A; Michal, S; Micheletti, M I; Miramonti, L; Mollerach, S; Montanet, F; Morejon, L; Morello, C; Mostafá, M; Müller, A L; Muller, M A; Mulrey, K; Mussa, R; Muzio, M; Namasaka, W M; Nasr-Esfahani, A; Nellen, L; Nicora, G; Niculescu-Oglinzanu, M; Niechciol, M; Nitz, D; Norwood, I; Nosek, D; Novotny, V; Nožka, L; Nucita, A; Núñez, L A; Oliveira, C; Palatka, M; Pallotta, J; Papenbreer, P; Parente, G; Parra, A; Pawlowsky, J; Pech, M; Pękala, J; Pelayo, R; Peña-Rodriguez, J; Pereira Martins, E E; Perez Armand, J; Pérez Bertolli, C; Perrone, L; Petrera, S; Petrucci, C; Pierog, T; Pimenta, M; Pirronello, V; Platino, M; Pont, B; Pothast, M; Privitera, P; Prouza, M; Puyleart, A; Querchfeld, S; Rautenberg, J; Ravignani, D; Reininghaus, M; Ridky, J; Riehn, F; Risse, M; Rizi, V; Rodrigues de Carvalho, W; Rodriguez Rojo, J; Roncoroni, M J; Rossoni, S; Roth, M; Roulet, E; Rovero, A C; Ruehl, P; Saftoiu, A; Saharan, M; Salamida, F; Salazar, H; Salina, G; Sanabria Gomez, J D; Sánchez, F; Santos, E M; Santos, E; Sarazin, F; Sarmento, R; Sarmiento-Cano, C; Sato, R; Savina, P; Schäfer, C M; Scherini, V; Schieler, H; Schimassek, M; Schimp, M; Schlüter, F; Schmidt, D; Scholten, O; Schoorlemmer, H; Schovánek, P; Schröder, F G; Schulte, J; Schulz, T; Sciutto, S J; Scornavacche, M; Segreto, A; Sehgal, S; Shellard, R C; Sigl, G; Silli, G; Sima, O; Smau, R; Šmída, R; Sommers, P; Soriano, J F; Squartini, R; Stadelmaier, M; Stanca, D; Stanič, S; Stasielak, J; Stassi, P; Streich, A; Suárez-Durán, M; Sudholz, T; Suomijärvi, T; Supanitsky, A D; Szadkowski, Z; Tapia, A; Taricco, C; Timmermans, C; Tkachenko, O; Tobiska, P; Todero Peixoto, C J; Tomé, B; Torrès, Z; Travaini, A; Travnicek, P; Trimarelli, C; Tueros, M; Ulrich, R; Unger, M; Vaclavek, L; Vacula, M; Valdés Galicia, J F; Valore, L; Varela, E; Vásquez-Ramírez, A; Veberič, D; Ventura, C; Vergara Quispe, I D; Verzi, V; Vicha, J; Vink, J; Vorobiov, S; Wahlberg, H; Watanabe, C; Watson, A A; Weindl, A; Wiencke, L; Wilczyński, H; Wittkowski, D; Wundheiler, B; Yushkov, A; Zapparrata, O; Zas, E; Zavrtanik, D; Zavrtanik, M; Zehrer, L; ,
Instantons, which are nonperturbative solutions to Yang-Mills equations, provide a signal for the occurrence of quantum tunneling between distinct classes of vacua. They can give rise to decays of particles otherwise forbidden. Using data collected at the Pierre Auger Observatory, we search for signatures of such instanton-induced processes that would be suggestive of super-heavy particles decaying in the Galactic halo. These particles could have been produced during the post-inflationary epoch and match the relic abundance of dark matter inferred today. The nonobservation of the signatures searched for allows us to derive a bound on the reduced coupling constant of gauge interactions in the dark sector: α_{X}≲0.09, for 10^{9}≲M_{X}/GeV<10^{19}. Conversely, we obtain that, for instance, a reduced coupling constant α_{X}=0.09 excludes masses M_{X}≳3×10^{13}  GeV. In the context of dark matter production from gravitational interactions alone, we illustrate how these bounds are complementary to those obtained on the Hubble rate at the end of inflation from the nonobservation of tensor modes in the cosmological microwave background.
PMID: 36827568
ISSN: 1079-7114
CID: 5911432

Trends in Cannabis-positive Urine Toxicology Test Results: US Veterans Health Administration Emergency Department Patients, 2008 to 2019

Fink, David S; Malte, Carol; Cerdá, Magdalena; Mannes, Zachary L; Livne, Ofir; Martins, Silvia S; Keyhani, Salomeh; Olfson, Mark; McDowell, Yoanna; Gradus, Jaimie L; Wall, Melanie M; Sherman, Scott; Maynard, Charles C; Saxon, Andrew J; Hasin, Deborah S
OBJECTIVES:This study aimed to examine trends in cannabis-positive urine drug screens (UDSs) among emergency department (ED) patients from 2008 to 2019 using data from the Veterans Health Administration (VHA) health care system, and whether these trends differed by age group (18-34, 35-64, and 65-75 years), sex, and race, and ethnicity. METHOD:VHA electronic health records from 2008 to 2019 were used to identify the percentage of unique VHA patients seen each year at an ED, received a UDS, and screened positive for cannabis. Trends in cannabis-positive UDS were examined by age, race and ethnicity, and sex within age groups. RESULTS:Of the VHA ED patients with a UDS, the annual prevalence positive for cannabis increased from 16.42% in 2008 to 27.2% in 2019. The largest increases in cannabis-positive UDS were observed in the younger age groups. Male and female ED patients tested positive for cannabis at similar levels. Although the prevalence of cannabis-positive UDS was consistently highest among non-Hispanic Black patients, cannabis-positive UDS increased in all race and ethnicity groups. DISCUSSION:The increasing prevalence of cannabis-positive UDS supports the validity of previously observed population-level increases in cannabis use and cannabis use disorder from survey and administrative records. Time trends via UDS results provide additional support that previously documented increases in self-reported cannabis use and disorder from surveys and claims data are not spuriously due to changes in patient willingness to report use as it becomes more legalized, or due to greater clinical attention over time.
PMCID:10766071
PMID: 37934524
ISSN: 1935-3227
CID: 5911632

Chronic pain, cannabis legalisation, and cannabis use disorder among patients in the US Veterans Health Administration system, 2005 to 2019: a repeated, cross-sectional study

Hasin, Deborah S; Wall, Melanie M; Alschuler, Daniel M; Mannes, Zachary L; Malte, Carol; Olfson, Mark; Keyes, Katherine M; Gradus, Jaimie L; Cerdá, Magdalena; Maynard, Charles C; Keyhani, Salomeh; Martins, Silvia S; Fink, David S; Livne, Ofir; McDowell, Yoanna; Sherman, Scott; Saxon, Andrew J
BACKGROUND:Cannabis use disorder is associated with considerable comorbidity and impairment in functioning, and prevalence is increasing among adults with chronic pain. We aimed to assess the effect of introduction of medical cannabis laws (MCL) and recreational cannabis laws (RCL) on the increase in cannabis use disorder among patients in the US Veterans Health Administration (VHA). METHODS:Data from patients with one or more primary care, emergency, or mental health visit to the VHA in 2005-19 were analysed using 15 repeated cross-sectional VHA electronic health record datasets (ie, one dataset per year). Patients in hospice or palliative care were excluded. Patients were stratified as having chronic pain or not using an American Pain Society taxonomy of painful medical conditions. We used staggered-adoption difference-in-difference analyses to estimate the role of MCL and RCL enactment in the increases in prevalence of diagnosed cannabis use disorder and associations with presence of chronic pain, accounting for the year that state laws were enacted. We did this by fitting a linear binomial regression model stratified by pain, with time-varying cannabis law status, fixed effects for state, categorical year, time-varying state-level sociodemographic covariates, and patient covariates (age group [18-34 years, 35-64 years, and 65-75 years], sex, and race and ethnicity). FINDINGS:Between 2005 and 2019, 3 234 382-4 579 994 patients were included per year. Among patients without pain in 2005, 5·1% were female, mean age was 58·3 (SD 12·6) years, and 75·7%, 15·6%, and 3·6% were White, Black, and Hispanic or Latino, respectively. In 2019, 9·3% were female, mean age was 56·7 (SD 15·2) years, and 68·1%, 18·2%, and 6·5% were White, Black, and Hispanic or Latino, respectively. Among patients with pain in 2005, 7·1% were female, mean age was 57·2 (SD 11·4) years, and 74·0%, 17·8%, and 3·9% were White, Black, and Hispanic or Latino, respectively. In 2019, 12·4% were female, mean age was 57·2 (SD 13·8) years, and 65·3%, 21·9%, and 7·0% were White, Black, and Hispanic or Latino, respectively. Among patients with chronic pain, enacting MCL led to a 0·135% (95% CI 0·118-0·153) absolute increase in cannabis use disorder prevalence, with 8·4% of the total increase in MCL-enacting states attributable to MCL. Enacting RCL led to a 0·188% (0·160-0·217) absolute increase in cannabis use disorder prevalence, with 11·5% of the total increase in RCL-enacting states attributable to RCL. In patients without chronic pain, enacting MCL and RCL led to smaller absolute increases in cannabis use disorder prevalence (MCL: 0·037% [0·027-0·048], 5·7% attributable to MCL; RCL: 0·042% [0·023-0·060], 6·0% attributable to RCL). Overall, associations of MCL and RCL with cannabis use disorder were greater in patients with chronic pain than in patients without chronic pain. INTERPRETATION:Increasing cannabis use disorder prevalence among patients with chronic pain following state legalisation is a public health concern, especially among older age groups. Given cannabis commercialisation and widespread public beliefs about its efficacy, clinical monitoring of cannabis use and discussion of the risk of cannabis use disorder among patients with chronic pain is warranted. FUNDING:NIDA grant R01DA048860, New York State Psychiatric Institute, and the VA Centers of Excellence in Substance Addiction Treatment and Education.
PMID: 37837985
ISSN: 2215-0374
CID: 5911612

Chronic Pain, Cannabis Legalization and Cannabis Use Disorder in Veterans Health Administration Patients, 2005 to 2019

Hasin, Deborah S; Wall, Melanie M; Alschuler, Dan; Mannes, Zachary L; Malte, Carol; Olfson, Mark; Keyes, Katherine M; Gradus, Jaimie L; Cerdá, Magdalena; Maynard, Charles C; Keyhani, Salomeh; Martins, Silvia S; Fink, David S; Livne, Ofir; McDowell, Yoanna; Sherman, Scott; Saxon, Andrew J
BACKGROUND/UNASSIGNED:The risk for cannabis use disorder (CUD) is elevated among U.S. adults with chronic pain, and CUD rates are disproportionately increasing in this group. Little is known about the role of medical cannabis laws (MCL) and recreational cannabis laws (RCL) in these increases. Among U.S. Veterans Health Administration (VHA) patients, we examined whether MCL and RCL effects on CUD prevalence differed between patients with and without chronic pain. METHODS/UNASSIGNED:Patients with ≥1 primary care, emergency, or mental health visit to the VHA and no hospice/palliative care within a given calendar year, 2005-2019 (yearly n=3,234,382 to 4,579,994) were analyzed using VHA electronic health record (EHR) data. To estimate the role of MCL and RCL enactment in the increases in prevalence of diagnosed CUD and whether this differed between patients with and without chronic pain, staggered-adoption difference-in-difference analyses were used, fitting a linear binomial regression model with fixed effects for state, categorical year, time-varying cannabis law status, state-level sociodemographic covariates, a chronic pain indicator, and patient covariates (age group [18-34, 35-64; 65-75], sex, and race and ethnicity). Pain was categorized using an American Pain Society taxonomy of painful medical conditions. OUTCOMES/UNASSIGNED:In patients with chronic pain, enacting MCL led to a 0·14% (95% CI=0·12%-0·15%) absolute increase in CUD prevalence, with 8·4% of the total increase in CUD prevalence in MCL-enacting states attributable to MCL. Enacting RCL led to a 0·19% (95%CI: 0·16%, 0·22%) absolute increase in CUD prevalence, with 11·5% of the total increase in CUD prevalence in RCL-enacting states attributable to RCL. In patients without chronic pain, enacting MCL and RCL led to smaller absolute increases in CUD prevalence (MCL: 0·037% [95%CI: 0·03, 0·05]; RCL: 0·042% [95%CI: 0·02, 0·06]), with 5·7% and 6·0% of the increases in CUD prevalence attributable to MCL and RCL. Overall, MCL and RCL effects were significantly greater in patients with than without chronic pain. By age, MCL and RCL effects were negligible in patients age 18-34 with and without pain. In patients age 35-64 with and without pain, MCL and RCL effects were significant (p<0.001) but small. In patients age 65-75 with pain, absolute increases were 0·10% in MCL-only states and 0·22% in MCL/RCL states, with 9·3% of the increase in CUD prevalence in MCL-only states attributable to MCL, and 19.4% of the increase in RCL states attributable to RCL. In patients age 35-64 and 65-75, MCL and RCL effects were significantly greater in patients with pain. INTERPRETATION/UNASSIGNED:In patients age 35-75, the role of MCL and RCL in the increasing prevalence of CUD was greater in patients with chronic pain than in those without chronic pain, with particularly pronounced effects in patients with chronic pain age 65-75. Although the VHA offers extensive behavioral and non-opioid pharmaceutical treatments for pain, cannabis may seem a more appealing option given media enthusiasm about cannabis, cannabis commercialization activities, and widespread public beliefs about cannabis efficacy. Cannabis does not have the risk/mortality profile of opioids, but CUD is a clinical condition with considerable impairment and comorbidity. Because cannabis legalization in the U.S. is likely to further increase, increasing CUD prevalence among patients with chronic pain following state legalization is a public health concern. The risk of chronic pain increases as individuals age, and the average age of VHA patients and the U.S. general population is increasing. Therefore, clinical monitoring of cannabis use and discussion of the risk of CUD among patients with chronic pain is warranted, especially among older patients. RESEARCH IN CONTEXT/UNASSIGNED:
PMID: 37503049
CID: 5911592

Typology of laws restricting access to methadone treatment in the United States: A latent class analysis

Conway, Anna; Krawczyk, Noa; McGaffey, Frances; Doyle, Sheri; Baaklini, Vanessa; Marshall, Alison D; Treloar, Carla; Davis, Corey S; Colledge-Frisby, Samantha; Grebely, Jason; Cerdá, Magdalena
BACKGROUND:In the United States, methadone treatment for opioid use disorder is only available at opioid treatment programs (OTPs). In addition to federal regulations, states can enact laws which shape access to OTPs. We aimed to define classes of states according to restrictiveness of state OTP laws and examine population characteristics associated with class membership. METHODS:A set of laws was extracted from a database of statutes and regulations governing OTPs in 49 states and the District of Columbia as of June 2021. Latent class analysis of laws was used to estimate the probability of class membership for each state. Class-weighted multinomial logistic regression analysis assessed state-level correlates of class membership and adjusted Relative Risk Ratio (aRRR) and 95% confidence intervals (95%CI) were generated. RESULTS:States (n = 50) were assigned to three classes; Class 1) High restrictiveness on patient experience, low restrictiveness on access to service (n = 13); Class 2) Medium restrictiveness on patient experience, high restrictiveness on access to service (n = 14); Class 3) Low restrictiveness on patient experience, low restrictiveness on access to service (n = 23). States with a higher probability of membership in Classes with higher restrictiveness had higher rates of unemployment (Class 1 vs Class 3, aRRR:1.24; 95%CI:1.06-1.45), and Black residents (Class 2 vs Class 3, aRRR:1.10; 95%CI:1.04-1.15), and lower likelihood of Medicaid coverage of methadone (Class 1 vs Class 3, aRRR:0.25; 95%CI:0.07-0.88). States with a higher probability of membership in Classes with higher restrictiveness also had higher rates of potential indicators for opioid use disorder treatment need, including rates of opioid dispensing (Class 1 vs Class 3, aRRR:1.06; 95%CI:1.02-1.10, Class 2 vs Class 3, aRRR:1.07; 95%CI:1.03-1.11) and HIV diagnoses attributed to injection (Class 1 vs Class 3, aRRR:3.92; 95%CI:1.25-12.22). CONCLUSIONS:States with indicators of greater potential need for opioid use disorder treatment have the most restrictions, raising concerns about unmet treatment need.
PMID: 37540917
ISSN: 1873-4758
CID: 5625682

Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study

Williams, Arthur Robin; Krawczyk, Noa; Hu, Mei-Chen; Harpel, Lexa; Aydinoglo, Nicole; Cerda, Magdalena; Rotrosen, John; Nunes, Edward V
BACKGROUND/UNASSIGNED:Approximately 1800 opioid treatment programs (OTPs) in the US dispense methadone to upwards of 400,000 patients with opioid use disorder (OUD) annually, operating under longstanding highly restrictive guidelines. OTPs were granted novel flexibilities beginning March 15, 2020, allowing for reduced visit frequency and extended take-home doses to minimize COVID exposure with great variation across states and sites. We sought to use electronic health records to compare retention in treatment, opioid use, and adverse events among patients newly entering methadone maintenance in the post-reform period in comparison with year-ago, unexposed, controls. METHODS/UNASSIGNED:Retrospective observational cohort study across 9 OTPs, geographically dispersed, in the National Institute of Drug Abuse (NIDA) Clinical Trials Network. Newly enrolled patients between April 15 and October 14, 2020 (post-COVID, reform period) v. March 15-September 14, 2019 (pre-COVID, control period) were assessed. The primary outcome was 6-month retention. Secondary outcomes were opioid use and adverse events including emergency department visits, hospitalizations, and overdose. FINDINGS/UNASSIGNED: INTERPRETATION/UNASSIGNED:Policies allowing for extended take-home schedules were not associated with worse retention or adverse events despite slightly elevated rates of measured opioid use while in care. Relaxed guidelines were not associated with measurable increased harms and findings could inform future studies with prospective trials. FUNDING/UNASSIGNED:USDHHSNIDACTNUG1DA013035-15.
PMCID:10751716
PMID: 38152421
ISSN: 2667-193x
CID: 5623252

Changes in arrests following decriminalization of low-level drug possession in Oregon and Washington

Davis, Corey S; Joshi, Spruha; Rivera, Bianca D; Cerdá, Magdalena
BACKGROUND:Despite evidence that the U.S. "War on Drugs" is associated with increases in drug-related harm and other negative outcomes, all U.S. states have long criminalized most drug possession. In early 2021, both Oregon and Washington became exceptions to this rule when they fully (Oregon) or partially (Washington) decriminalized possession of small amounts of all drugs. METHODS:We obtained arrest data for 2019 to 2021 for intervention states (Oregon and Washington) and control states (Colorado, Idaho, Montana, and Nevada). We calculated monthly rates for arrests overall and for violent crimes, drug possession, equipment possession, non-drug crimes, and a set of low-level crimes termed displaced arrests. Using an interrupted time series analysis, we examined changes in monthly arrest rates after the implementation of policy change in Oregon and Washington compared to control states. RESULTS:In Oregon, there were 3 fewer drug possession arrests per 100,000 in the month after the policy change; the rate decreased throughout the post-implementation period. In Washington, there were almost 5 fewer drug possession arrests per 100,000 in the month following policy change, and the rate remained stable thereafter. Both declines were significantly greater than in comparison states. There were also statistically significant reductions in arrests for possession of drug equipment in Washington and a significant increase in displaced arrests in Oregon. There were no significant changes in overall arrests, non-drug arrests or arrests for violent crime in either state, relative to controls. CONCLUSION:This analysis demonstrates that it is possible for state drug decriminalization policies to dramatically reduce arrests for drug possession without increasing arrests for violent crimes, potentially reducing harm to people who use drugs and their communities. Additional research is needed to determine whether these legal reforms were associated with changes in overdose rates and other drug-related harms.
PMID: 37567089
ISSN: 1873-4758
CID: 5619122